Cardiovascular diseases remain a leading cause of mortality, often due to late detection and intervention. Traditional diagnostic methods may not provide a comprehensive risk assessment, hindering personalized treatment strategies. There is a need for more precise and early diagnostic tools to improve patient outcomes and reduce healthcare costs associated with cardiovascular events.

Cardio Diagnostics offers an AI-driven Multi-Omics™ engine that analyzes both epigenetic and genetic markers to provide a comprehensive cardiovascular risk assessment. Their technology enables early diagnosis and prediction of a patient's three-year risk of experiencing a coronary heart disease event, such as a heart attack. By integrating genome-wide genetic, epigenetic, and clinical data, the platform generates actionable predictive models. This approach facilitates personalized care management, monitors treatment effectiveness, and optimizes health outcomes through precise measurements and scalable techniques.

AI-driven Multi-Omics™ engine integrating genetic, epigenetic, and clinical data

Predictive models for assessing the three-year risk of coronary heart disease events

Clinical blood tests for the detection and management of coronary heart disease

Digital and Taqman PCR-based assays for precise measurement of epigenetic and genetic markers

Scalable platform for seamless integration and analysis of diverse datasets

Non-clinical solutions include a cardiovascular risk intelligence platform for healthcare stakeholders

Research use only (RUO) platform to support the discovery and validation of novel biopharmaceuticals

The primary target audience includes healthcare providers, provider organizations, employers, brokers and benefits consultants, government entities, and clinical researchers focused on cardiovascular disease management and prevention.